

Indoco's Net Profit Q-o-Q grows at 29%

Mumbai, January 25, 2018: Indoco Remedies posted revenues of ₹ 274.2 crore during the third quarter of FY 2017-18, as against ₹ 272.2 crores, for the same quarter last year. The Company's Profit After Tax is at ₹ 22.7 crores as against ₹ 17.6 crores, for the same quarter last year.

Commenting on this development, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "The third quarter saw progressive growth in the Indian Business. On the International Business front, Europe and Emerging Markets too showed encouraging sales trend. Operating margins improved with EBIDTA at 16 % of sales and growth in PAT at 29%, over same quarter last year".

For the quarter ended December'17, the financials are as under:

(₹ in Crores)

Particulars	Oct'17- December'17	Oct'16- December'16
Net Revenue	274.2	272.2
EBIDTA	43.2	39.2
Profit After Tax	22.7	17.6
EPS (Face value ₹ 2/-) (Not annualized)	2.46	1.91

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 165 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-

South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com